can be mistaken for early pregnancy. We recommend ␤-hCG testing for pregnancy be performed before apheresis and/or before beginning high-dose chemotherapy, but not We studied six women whose blood cells were being colclose to the time of blood cell collection to exclude falselected by apheresis for an autotransplant after rhG-CSF positive tests. priming. Baseline studies of serum ␤-hCG were negative (Ͻ3 mIU/ml; Stratus hCG fluorometric enzyme immuno-SG Ericson Use of Ceprate CD34-positive selection device only for purging tumour cells from marrow for autologous transplantation, which is quite a different matter.
system for depletion of T cells in allogeneic
It is reported that CellPro (Bothell, WA, USA) are transplantation developing additional steps using T cell-specific antibodies for positive selection. 2, 5 We have little doubt that the combined methodology could prevent GVHD. However, 13 years of clinical experience and a wealth of animal exper-A recent paper by Clarke et al 1 compares the Ceprate imentation teaches us that there will then be an increased CD34
+ cell selection process with cell lysis using CAMrisk of graft rejection due to residual host T cells. 6 This PATH-1M antibody for depletion of T cells in allogeneic transplants. The advantage of the Ceprate process may be risk may be reduced by the administration of large numbers that donor T cells can be recovered from the unabsorbed of stem cells from peripheral blood donations, but addtional fraction and stored for later infusion in the event of relapse.
immunosuppression of the recipient may still be necessary.
If very large numbers of T cells are required for donor
That is why we proposed the use of cell-depleting monolymphocyte infusions, this might be useful, especially when clonal antibodies which deal with the T cells in both donor the donors are unrelated. Nevertheless, for most practical and recipient. We believe that the only real measure of purposes, it would be simple enough to obtain sufficient T effectiveness will be in the clinical results rather than the cells by cryopreservation of a small proportion of untreated ever more detailed dissection of apparent depletion in vitro. blood cells.
We are pleased to note that evidence for clinical efficacy However, we are concerned that the transplant comand safety is now required for each indication for which munity may be giving too little attention to the fundamental the 'CE' mark is granted, in an analogous fashion to the aspects of T cell depletion using Ceprate. Firstly, is it sufapproval system for drugs. 
